Biotech & Pharma
Sanifit is a clinical-stage biopharmaceutical company dedicated to the development of treatments for calcification-related diseases. The company started its activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the United States.
Sanifit’s lead product is SNF472, a molecule that is a potent selective inhibitor of hydroxyapatite crystallization, the common final stage leading to the development of cardiovascular calcifications. SNF472 is in the clinical phase for the treatment of calciphylaxis and for the treatment of peripheral arterial disease in dialysis patients.
Therapeutic pipeline:
Pipeline OTC/diagnostics
Sanifit’s technology is based on the use of crystallization inhibitors as a mechanism of action for the treatment of diseases related to pathological calcification. This technology is protected by more than 120 patents worldwide, grouped in 11 patent families.
Cardiovascular calcifications.
Nephrology.
Oral conditions.
Bone diseases.
Sanifit Therapeutics S. A.
Address: Europa Building, Parc Bit, Ctra Valldemossa, Km 7.4, North, 07121 Palma, Illes Balears
E-mail: info@sanifit.com
Phone: +34 971 439 925
